Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

Acta Neuropsychiatrica

Volumn 21, Issue 5, 2009, Pages 239-245

  Bernardo, Michelle ^a   Dodd, Seetal ^a   Gama, Clarissa S ^d   Copolov, David L ^c,e   Dean, Olivia ^a,c   Kohlmann, Kristy ^a,c   Jeavons, Susan ^c   Schapkaitz, Ian ^c   Anderson Hunt, Murray ^c   Bush, Ashley I ^c   Berk, Michael ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Alcohol; Bipolar disorder; Caffeine; Clinical trial; N acetyl cysteine; Smoking; Substance use

Indexed keywords

ACETYLCYSTEINE; CAFFEINE; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 70349304388     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2009.00415.x     Document Type: Article

References (37)

1. Berk M, Dodd S, Berk L. The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005 59 : 229 239. (Pubitemid 40897192)
2. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990 264 : 2511 2518.
3. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999 60 : 733 740.
4. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993 9 : 441 449.
5. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001 3 : 181 188.
6. Castro AA, Moretti M, Casagrande TS et al. Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam. Pharmacol Biochem Behav 2009 91 : 636 642.
7. Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996 55 : 33 43.
8. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004 19 : 89 95.
9. Machado-Vieira R, Andreazza AC, Viale CI et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007 421 : 33 36.
10. Andreazza AC, Cassini C, Rosa AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007 41 : 523 529.
11. Frey BN, Andreazza AC, Kunz M et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 : 283 285.
12. Grignon S, Chianetta JM. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 : 365 369.
13. Gama CS, Berk M, Andreazza AC, Kapczinski F, Belmonte-de-Abreu P. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev Bras Psiquiatr 2008 30 : 337 340.
14. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006 30 : 512 515.
15. Gama CS, Salvador M, Andreazza AC et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci Lett 2008 433 : 270 273.
16. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008 33 : 166 180.
17. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005 10 : 900 919.
18. Wozniak B, Musialkiewicz D, Wozniak A et al. Lack of changes in the concentration of thiobarbituric acid-reactive substances (TBARS) and in the activities of erythrocyte antioxidant enzymes in alcohol-dependent patients after detoxification. Med Sci Monit 2008 14 : CR32 CR36.
19. Baker DA, McFarland K, Lake RW et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neuroscience 2003 6 : 743 749.
20. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005 25 : 6389 6393.
21. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003 23 : 3531 3537.
22. Madayag A, Lobner D, Kau KS et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007 27 : 13968 13976.
23. Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2008 63 : 338 340.
24. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007 62 : 652 657.
25. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989 36 : 127 131.
26. Holdiness MR. Clinical pharmokinetics of N-acetylcysteine. Clincal Pharmokinetics 1991 20 : 123 134.
27. Dean O, van den Buuse M, Copolov DL, Berk M, Bush AI. N-acetylcysteine treatment inhibits depletion of brain glutathione levels in rats: implications for schizophrenia. Int J Neuropsychopharmacol 2004 7 : S262.
28. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport 2000 11 : 2491 2493.
29. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995 52 : 559 564.
30. Rothstein JD, Bristol LA, Hosler B, Brown RH Jr., Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994 91 : 4155 4159.
31. Koppal T, Drake J, Butterfield DA. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochimica et Biophysica Acta 1999 1453 : 407 411.
32. Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 1994 91 : 7496 7500.
33. Staal FJ, Anderson MT, Herzenberg LA. Redox regulation of activation of NF-kappa B transcription factor complex: effects of N-acetylcysteine. Methods Enzymol 1995 252 : 168 174.
34. Ferrari G, Yan CY, Greene LA. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 1995 15 : 2857 2866.
35. Berk M, Copolov D, Dean O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008 64 : 361 368.
36. Berk M, Copolov DL, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008 64 : 468 475.
37. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD : U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.